Menu Icon


The ADMA ADvantage Ig™ program is a dedicated and comprehensive patient support hub created for eligible patients

ADMA ADvantage Ig provides resources to help to make savings and support simple

Photo of portrayed patient holding the ADMA ADvantage Ig Patient Support Card
112666_GettyImages-81859875_RGB 1 (3)

ADMA ADvantage Ig provides resources to help to make savings and support simple

  • Helps eligible patients pay as little as possible for ASCENIV™, maximizes insurance benefits, and minimizes overall treatment costs
  • Helps locate alternative funding and other payment options, such as nonprofit patient assistance foundations
  • Supports providers and staff with benefits verification to determine ASCENIV coverage, including out-of-pocket costs, and determines payer requirements
  • Assists with claims, reimbursement support, and appeals
  • ASCENIV unique HCPCS code J1554

Enroll your patients today!

ASCENIV Enrollment Form | Logo for ADMA ADvantage Ig Patient Support Program
Group 199

Download the PDF or complete the online form

Count on our ADvantage Ig program to help patients start and stay on ASCENIV


ASCENIV (immune globulin intravenous, human – slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).


Important Safety Information for ASCENIV™


  • Thrombosis may occur with immune globulin (IGIV) products, including ASCENIV. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IVIG products in predisposed patients.
  • Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. ASCENIV does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction or renal failure, administer ASCENIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.